Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance

Michelle Doyle; Lenka A Vodstrcil; Erica L Plummer; Ivette Aguirre; Christopher K Fairley; Catriona S Bradshaw

doi:10.1093/ofid/ofaa291

Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance

Open Forum Infect Dis. 2020 Jul 13;7(8):ofaa291. doi: 10.1093/ofid/ofaa291. eCollection 2020 Aug.

Authors

Michelle Doyle¹, Lenka A Vodstrcil^{1

2}, Erica L Plummer^{1

2}, Ivette Aguirre¹, Christopher K Fairley^{1

2}, Catriona S Bradshaw^{1

2}

Affiliations

¹ Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia.
² Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Abstract

In the era of increasing macrolide- and quinolone-resistant Mycoplasma genitalium (MG), we report the efficacy of 2 nonquinolone antimicrobials in patients with limited treatment options. Pristinamycin + doxycycline cured 75% (95% CI, 64%-85%), and minocycline cured 71% (95% CI, 54%-85%) of cases. These data provide useful estimates to inform clinical practice.

Keywords: Mycoplasma genitalium; multidrug failure; sexually transmitted infections; treatment.